<p>This randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. All participants in this study were female. RNA sequencing data from the same patients were published under <a href="https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bihttps://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001863.v1.p1">phs001863</a>. Subject aliases are the same in the two datasets.</p>

Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin    +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by    Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast    Cancer: DNA Sequencing

Breast Neoplasms study with Targeted-Capture data on dbGaP (268 participants)

phs003801 — Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin    +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by    Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast    Cancer: DNA Sequencing

Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer: DNA Sequencing

Description

Applying For Access

Summary